A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-09-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiacarcinomatumormetastaticprior
  Phrases that lowered it: myelomadexamethasoneoraldosehormone
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 4.5% (lowers risk) · Sponsor's track record
• Collaborators: 4 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 111 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 446 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 96.0% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 24.1% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 8083 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) NCT03014648 · started 2017 · scored riskier than 90% of active trials completed
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma NCT03513952 · started 2019 · scored riskier than 84% of active trials completed
• Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer NCT03272217 · started 2017 · scored riskier than 83% of active trials terminated
• Atezolizumab Immunotherapy in Patients With Advanced NSCLC NCT03102242 · started 2017 · scored riskier than 80% of active trials completed
• Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer NCT04936230 · started 2022 · scored riskier than 94% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.